FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4289515982> ?p ?o ?g. }

• W4289515982 endingPage "101585" @default.
• W4289515982 startingPage "101585" @default.
• W4289515982 abstract "Vaccines have been demonstrated to protect against high-risk human papillomavirus infection (HPV), including HPV-16/18, and cervical lesions among HIV negative women. However, their efficacy remains uncertain for people living with HIV (PLHIV).We systematically reviewed available evidence on HPV vaccine on immunological, virological, or other biological outcomes in PLHIV.We searched five electronic databases (PubMed, Medline and Embase, clinicaltrials.gov and the WHO clinical trial database) for longitudinal prospective studies reporting immunogenicity, virological, cytological, histological, clinical or safety endpoints following prophylactic HPV vaccination among PLHIV. We included studies published by February 11th, 2021. We summarized results, assessed study quality, and conducted meta-analysis and subgroup analyses, where possible.We identified 43 publications stemming from 18 independent studies (Ns =18), evaluating the quadrivalent (Ns =15), bivalent (Ns =4) and nonavalent (Ns =1) vaccines. A high proportion seroconverted for the HPV vaccine types. Pooled proportion seropositive by 28 weeks following 3 doses with the bivalent, quadrivalent, and nonavalent vaccines were 0.99 (95% confidence interval: 0.95-1.00, Ns =1), 0.99 (0.98-1.00, Ns =9), and 1.00 (0.99-1.00, Ns =1) for HPV-16 and 0.99 (0.96-1.00, Ns =1), 0.94 (0.91-0.96, Ns =9), and 1.00 (0.99-1.00, Ns =1) for HPV-18, respectively. Seropositivity remained high among people who received 3 doses despite some declines in antibody titers and lower seropositivity over time, especially for HPV-18, for the quadrivalent than the bivalent vaccine, and for HIV positive than negative individuals. Seropositivity for HPV-18 at 29-99 weeks among PLHIV was 0.72 (0.66-0.79, Ns =8) and 0.96 (0.92-0.99, Ns =2) after 3 doses of the quadrivalent and bivalent vaccine, respectively and 0.94 (0.90-0.98, Ns =3) among HIV-negative historical controls. Evidence suggests that the seropositivity after vaccination declines over time but it can lasts at least 2-4 years. The vaccines were deemed safe among PLHIV with few serious adverse events. Evidence of HPV vaccine efficacy against acquisition of HPV infection and/or associated disease from the eight trials available was inconclusive due to the low quality.PLHIV have a robust and safe immune response to HPV vaccination. Antibody titers and seropositivity rates decline over time but remain high. The lack of a formal correlate of protection and efficacy results preclude definitive conclusions on the clinical benefits. Nevertheless, given the burden of HPV disease in PLHIV, although the protection may be shorter or less robust against HPV-18, the robust immune response suggests that PLHIV may benefit from receiving HPV vaccination after acquiring HIV. Better quality studies are needed to demonstrate the clinical efficacy among PLHIV.World Health Organization. MRC Centre for Global Infectious Disease Analysis, Canadian Institutes of Health Research, UK Medical Research Council (MRC)." @default.
• W4289515982 created "2022-08-03" @default.
• W4289515982 creator A5000120704 @default.
• W4289515982 creator A5003035646 @default.
• W4289515982 creator A5003888696 @default.
• W4289515982 creator A5004791106 @default.
• W4289515982 creator A5026481326 @default.
• W4289515982 creator A5029222455 @default.
• W4289515982 creator A5031835550 @default.
• W4289515982 creator A5038279355 @default.
• W4289515982 creator A5053674919 @default.
• W4289515982 creator A5060977168 @default.
• W4289515982 creator A5066499765 @default.
• W4289515982 creator A5072528874 @default.
• W4289515982 date "2022-10-01" @default.
• W4289515982 modified "2023-09-24" @default.
• W4289515982 title "Immunogenicity, safety, and efficacy of the HPV vaccines among people living with HIV: A systematic review and meta-analysis" @default.
• W4289515982 cites W1993945172 @default.
• W4289515982 cites W2050664909 @default.
• W4289515982 cites W2053081767 @default.
• W4289515982 cites W2073555467 @default.
• W4289515982 cites W2081047239 @default.
• W4289515982 cites W2085181701 @default.
• W4289515982 cites W2107328434 @default.
• W4289515982 cites W2108018524 @default.
• W4289515982 cites W2114986710 @default.
• W4289515982 cites W2119545652 @default.
• W4289515982 cites W2121732950 @default.
• W4289515982 cites W2125435699 @default.
• W4289515982 cites W2139168999 @default.
• W4289515982 cites W2139808322 @default.
• W4289515982 cites W2148969651 @default.
• W4289515982 cites W2155314494 @default.
• W4289515982 cites W2156098321 @default.
• W4289515982 cites W2157258852 @default.
• W4289515982 cites W2165649863 @default.
• W4289515982 cites W2174946562 @default.
• W4289515982 cites W2259185189 @default.
• W4289515982 cites W2286765507 @default.
• W4289515982 cites W2419027987 @default.
• W4289515982 cites W246286872 @default.
• W4289515982 cites W2472221349 @default.
• W4289515982 cites W2514934032 @default.
• W4289515982 cites W2590070418 @default.
• W4289515982 cites W2601303878 @default.
• W4289515982 cites W2605365014 @default.
• W4289515982 cites W2737658237 @default.
• W4289515982 cites W2747684038 @default.
• W4289515982 cites W2752368216 @default.
• W4289515982 cites W2757417278 @default.
• W4289515982 cites W2765445603 @default.
• W4289515982 cites W2769206492 @default.
• W4289515982 cites W2769565077 @default.
• W4289515982 cites W2777712302 @default.
• W4289515982 cites W2793496473 @default.
• W4289515982 cites W2796316611 @default.
• W4289515982 cites W2804919794 @default.
• W4289515982 cites W2806229809 @default.
• W4289515982 cites W2834937974 @default.
• W4289515982 cites W2887005618 @default.
• W4289515982 cites W2895409626 @default.
• W4289515982 cites W2902202108 @default.
• W4289515982 cites W2928100430 @default.
• W4289515982 cites W2955245499 @default.
• W4289515982 cites W2970729270 @default.
• W4289515982 cites W2975673647 @default.
• W4289515982 cites W2981365593 @default.
• W4289515982 cites W2990069179 @default.
• W4289515982 cites W2993250673 @default.
• W4289515982 cites W2999303548 @default.
• W4289515982 cites W2999405166 @default.
• W4289515982 cites W3006288925 @default.
• W4289515982 cites W3007477460 @default.
• W4289515982 cites W3009958407 @default.
• W4289515982 cites W3027175095 @default.
• W4289515982 cites W3027601268 @default.
• W4289515982 cites W3036651224 @default.
• W4289515982 cites W3041474312 @default.
• W4289515982 cites W3090300247 @default.
• W4289515982 cites W3099220846 @default.
• W4289515982 cites W3113789114 @default.
• W4289515982 cites W3122535456 @default.
• W4289515982 cites W3125106216 @default.
• W4289515982 cites W3127834874 @default.
• W4289515982 cites W3128646645 @default.
• W4289515982 cites W3130185476 @default.
• W4289515982 cites W3133790016 @default.
• W4289515982 cites W4210779844 @default.
• W4289515982 cites W4237266603 @default.
• W4289515982 cites W4294215472 @default.
• W4289515982 doi "https://doi.org/10.1016/j.eclinm.2022.101585" @default.
• W4289515982 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35936024" @default.
• W4289515982 hasPublicationYear "2022" @default.
• W4289515982 type Work @default.
• W4289515982 citedByCount "11" @default.
• W4289515982 countsByYear W42895159822022 @default.
• W4289515982 countsByYear W42895159822023 @default.
• W4289515982 crossrefType "journal-article" @default.

• next